arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

EXELIXIS, INC.

EXEL
$56.72 ▼ -1.43 (-2.45%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
68 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
90
Health
Excellent
Bullish
auto_awesome

Analytical Summary

EXELIXIS, INC. shows strong fundamentals with top-quartile Return on Common Equity (%) and Profit Margin (%). The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $14.2B
Dividend Yield
Revenue Growth 10.6%
Op. Margin 39.5%
ROIC 10.6%
FCF / Share $1.20
Trailing P/E 66.7x
Price / Book 7.7x
FCF Yield 2.1%
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$628.69M
↑ +10.6%
Net Income Profit after all expenses
$212.05M
↑ +14.7%
Operating Margin Operating profit as % of sales
39.5%
↓ -4.0% 92th
FCF / Share Free cash flow per share
$1.20
↑ +23.8%
Long-Term Debt Long-term obligations
$0.00
trending_up

Bullish Indicators

  • Operating Margin (%)Operating Margin (%) is in the top quartile
  • Profit Margin (%)Profit Margin (%) is in the top quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability
94
Returns
95
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters